Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.

Biochimica et biophysica acta. Reviews on cancer - 1 Aug 2020

Li Tian-Jiao, Wang Wen-Quan, Yu Xian-Jun, Liu Liang

Abstract excerpt

Cancer regression often fails after systemic immune activation, especially for solid tumors due to their local immunosuppressive microenvironments. Among these, the pancreatic cancer microenvironment is unique and an important reason for resistance to anti-cancer treatments that include immunotherapy. In this review, the three main "BAD" characteristics that create and maintain this immunosuppressive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Share to T-Lymphocytes, Cytotoxic

Share to Tumor Escape

Source

Identifiers

PMID: 32531324
DOI: 10.1016/j.bbcan.2020.188384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.PMID 32531324Read ↗

Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.Semantic proximity Read ↗

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read ↗

Myeloid-derived suppressor cells and their role in pancreatic cancer.Semantic proximity Read ↗

Targeting tumor tolerance: A new hope for pancreatic cancer therapy?Semantic proximity Read ↗

Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic CancerSemantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

The role of CD8+ T-cells in colorectal cancer immunotherapySemantic proximity Read ↗

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapySemantic proximity Read ↗

Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic CancerSemantic proximity Read ↗

PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.Semantic proximity Read ↗

Precision Medicine: IL-1RA and Pancreatic Cancer OrganoidsSemantic proximity Read ↗

Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.